Tiziana Life Sciences Ltd (TLSA) stock
TLSANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.61−0.01 (-1.61%)
Close on Nov 12, 2026Market cap $73.51MP/E –Yield –
Tiziana Life Sciences r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $10.28M, up 96.6% from the year before. The highest annual figure on record is $13.21M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.28M | +96.6% |
| FY2024 | Dec 31, 2024 | $5.23M | -35.5% |
| FY2023 | Dec 31, 2023 | $8.11M | -37.4% |
| FY2022 | Dec 31, 2022 | $12.96M | -1.9% |
| FY2021 | Dec 31, 2021 | $13.21M | +120.4% |
| FY2020 | Dec 31, 2020 | $5.99M | +61.4% |
| FY2019 | Dec 31, 2019 | $3.71M | -32.6% |
| FY2018 | Dec 31, 2018 | $5.51M | -8.4% |
| FY2017 | Dec 31, 2017 | $6.02M | +50.1% |
| FY2016 | Dec 31, 2016 | $4.01M | – |
See a number that looks wrong?